Obiphar SA
Obiphar reported total assets of 218,848 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jun 2026).
The score of Obiphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -20 % Total assets +46 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Obiphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −1,220 € | ||||
| Equity | 118,848 € | ||||
| Cash | 118,717 € | ||||
| EBITDA | 5,930 € | ||||
| Total assets | 218,848 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jun 2026
- Year ended 31 Dec 2024filed on 14 Jul 2025
- Year ended 31 Dec 2023filed on 06 Aug 2024
- Year ended 31 Dec 2022filed on 23 Aug 2023
- Year ended 31 Dec 2021filed on 16 Aug 2022
Obiphar's financial analysis
- Solvency54.3%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Obiphar
Obiphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0878.100.418
- VAT number
- BE0878100418
- Peppol
- Registered · 0208:0878100418 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 22 Dec 2005
- Registered office
- 7080 Frameries
- Latest accounts
- 2025 · filed on 30 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Obiphar (SA) has been based in Frameries since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 1,220 € and equity of 118,848 €; its revenue is not published. Its solvency stands at 54.3%, above the median of its sector (41.5%).
Companies similar to Obiphar
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DES Fripiers Retail sale of pharmaceutical products Brussels · balance sheet 218,485 €
- Apoteek't Groen Kruis Retail sale of pharmaceutical products Schoten · balance sheet 220,163 €
- Phidelta Pharma Retail sale of pharmaceutical products Liège · balance sheet 216,336 €
- Gilson Marie-Claire Retail sale of pharmaceutical products Vaux-sur-Sûre · balance sheet 221,736 €
- Apotheek J. DRAULANS Retail sale of pharmaceutical products Heusden-Zolder · balance sheet 215,560 €
- Pharmasolutions Retail sale of pharmaceutical products Linkebeek · balance sheet 215,436 €
- MDB Pharma Retail sale of pharmaceutical products Ghent · balance sheet 214,811 €
- Jufarma Retail sale of pharmaceutical products Charleroi · balance sheet 223,918 €
Frequently asked questions about Obiphar
What is the revenue of Obiphar?
Obiphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Obiphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0878100418 for Obiphar, if the company is VAT-registered. Its company number (CBE) is 0878.100.418.
Where is the registered office of Obiphar?
According to the CBE register, the registered office of Obiphar is in 7080 Frameries.
What is the equity of Obiphar?
At the close of the 2025 financial year, the equity of Obiphar amounts to 118,848 €, a solvency of 54.3% of total assets.
Who manages Obiphar?
The register lists 5 active mandates at Obiphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Obiphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →